AMENDED & RESTATED LICENSE AGREEMENTLicense Agreement • August 11th, 2017 • Selecta Biosciences Inc • Pharmaceutical preparations • New York
This Amended & Restated License Agreement (the “Agreement”), dated as of 31 May, 2017 (the “Effective Date”), is made by and between Shenyang Sunshine Pharmaceutical Co., Ltd., a Chinese Corporation, with an address at No. 3 A1 Road 10, Shenyang Economic and Technology Development Zone, Shenyang, China 110027 and its affiliates (“3SBio”), and Selecta Biosciences, Inc., a Delaware corporation, with an address at 480 Arsenal Street, Building One, Watertown, MA 02472 (“Selecta”). 3SBio and Selecta are sometimes hereinafter referred to each as a “Party” and collectively as the “Parties.”
June 6, 2017 Selecta Biosciences, Inc. Watertown, MA 02472 Attention: General Counsel Facsimile No.: 617-924-3454 RE: Letter Agreement Regarding Selecta/Spark License and Option Agreement Dear Sir or Madam:Letter Agreement • August 11th, 2017 • Selecta Biosciences Inc • Pharmaceutical preparations • New York
This letter agreement (the “Letter Agreement”) confirms the understanding between Selecta Biosciences, Inc. (“Selecta”) and Spark Therapeutics, Inc. (“Spark” and, together with Selecta, the “Parties”) with respect to certain rights, remedies and obligations of the Parties pursuant to that certain License and Option Agreement between the Parties dated as of December 2, 2016, as such agreement may be amended pursuant to its terms (the “License Agreement”) and that certain Stock Purchase Agreement between the Parties dated as of December 2, 2016, as such agreement may be amended pursuant to its terms (the “Stock Purchase Agreement”). Any capitalized terms not defined in this Letter Agreement shall have the meanings ascribed to them in the License Agreement or the Stock Purchase Agreement, as applicable.
